News Briefs
- 11/16/2026
As many mice as patients? Halifax area hospitals see soaring pest control costs
While port cities like Halifax see more rodents, the problem at the QEII Health Sciences Centre is unusual, Nova Scotia Health has acknowledged.
CBC News reported that the QEII complex—including Halifax Infirmary, Victoria General and Rehabilitation sites—saw its pest control budget increase 798% over the past five years.
"The volume of those sightings has increased exponentially over the last couple of years," Chris Smith, senior director for facilities operations at the NSH, told CBC.
"It's easy to say that we live in a port city and it's a thing, but it doesn't change our opinion and approaches that they don't belong in healthcare settings and we've got to do whatever we can to keep them out and keep those environments clean, sanitary and safe."
Read more: Keeping pests out this winter: What healthcare facilities need to know
- 11/16/2026
'It's not like a hotel. You can't just say there's an 11 a.m. check out': New directive for Alberta hospitals causes concern
Alberta Health Services is launching an initiative to try to see more patients discharged from hospital by 11 a.m.
"Patients are only discharged when their healthcare team determines they are medically ready and plans are in place. Patients will never be rushed to leave," reads explanatory text on an AHS survey to healthcare workers about the initiative.
Some were quick to raise concerns with Danielle Larivee, vice-president of United Nurses of Alberta telling CBC News, “It's not like a hotel. You can't just say there's an 11 a.m. check out—everybody's out.” She noted, however, that the directive does seem to be coming with the best of intentions, but making this a benchmark could be problematic.
“AHS has certainly indicated that no patient will be rushed to leave, but as soon as you're evaluating a target in any way, then managers get concerned about if they're not hitting what's the norm or feel pressured to reach the target,” she said.
- 11/16/2026
Are nicotine pouches harm reduction or just a new way for young people to start using the drug?
Nicotine pouches are more popular than ever. But debate remains on whether they serve as an effective tool to help people using nicotine do so in a relatively safer way, or if they've a novel way for people (especially younger ones) to try nicotine for the first time.
A recent article in the Journal of the American Pharmacists Association essentially concludes that it's both—and that pharmacists have a significant role to play.
"NPs occupy a dual position: a potential harm-reduction tool for adult smokers unable or unwilling to quit, and an emerging initiation pathway for nicotine-naïve individuals, especially youth," the paper read. "Pharmacists are uniquely positioned to counsel patients on these distinct risk profiles. Long-term clinical outcome data and evidence specific to pharmacy practice are urgently needed."
Researchers conduced a narrative evidence synthesis and eventually included 35 peer-reviewed articles. "NPs deliver nicotine via oral mucosal absorption with slower pharmacokinetics than combustible cigarettes and an abuse liability profile comparable to nicotine replacement therapy," they wrote.
Read more on this topic: It’s ‘just’ nicotine: What clinicians need to know about the rise of nicotine-only products
- 11/15/2026
N.L.’s top-billing ophthalmologist sued by two ex-patients
The suspended ophthalmologist who had been first on the list of Newfoundland and Labrador’s top-billing physicians is facing lawsuits from two former patients
In the suits, one patient alleges he became completely blinded on his right eye after Dr. Harry Dang performed a botched cataract surgery. The other alleges Dr. Dang performed a similar cataract procedure without considering the patient’s pre-existing degenerative eye condition that rendered the procedure dangerous.
- 11/15/2026
A better way to deliver topical pain relief?
A research team at the University of Alberta has developed a new microemulsion foam to provide topic pain relief for chronic conditions such as arthritis.
FoamaDerm®—as developed at the university’s Drug Development and Innovation Center—has “been shown to provide pain relief at just two per cent strength,” according to a story from U of A.
“In our studies, we showed that many of the dosage forms don’t release the drug appropriately, so I asked my students, ‘Can we make something better? Let’s try putting the active ingredient in a microemulsion instead,’” said Dr. Raimar Löbenberg, professor in the Faculty of Pharmacy and Pharmaceutical Sciences, who has been directing the project.
“We found that we doubled the release compared with other products on the market.”
- 11/13/2026
Drug manufacturer tells Canadian Duchenne muscular dystrophy patients it won't be supplying a certain drug going forward
The Globe and Mail reported Thursday that patients taking deflazacort for Duchenne muscular dystrophy (DMD) were informed in a letter from the company that makes the drug that it will not be supplying the treatment to Canada going forward.
According to Globe reporter Chris Hannay, German pharmaceutical firm Cheplapharm has distributed the drug to the Canadian market through Xediton Pharmaceuticals Inc. The latter sent a letter from Cheplapharm to Health Canada and DMD patient groups, citing supply-chain problems as the reason.
Specifically, Canada has been importing a portion of the drug the manufacturer had been making for the British market. But the company has had trouble sourcing a key ingredient for the drug and therefore won’t be supplying it to Britain anymore, cutting off the Canadian supply in the process.
The full (subscription access only) story from the Globe and Mail can be found here.